% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Oerlemans:576716,
      author       = {Oerlemans, Rick and Ruiz-Moreno, Angel Jonathan and Cong,
                      Yingying and Dinesh Kumar, Nilima and Velasco-Velazquez,
                      Marco A and Neochoritis, Constantinos G and Smith, Jolanda
                      and Reggiori, Fulvio and Groves, Matthew R and Dömling,
                      Alexander},
      title        = {{R}epurposing the {HCV} {NS}3-4{A} protease drug boceprevir
                      as {COVID}-19 therapeutics.},
      journal      = {RSC medicinal chemistry},
      volume       = {12},
      number       = {3},
      issn         = {2040-2503},
      address      = {Cambridge},
      publisher    = {Royal Society of Chemistry},
      reportid     = {PUBDB-2023-00887},
      pages        = {370 - 379},
      year         = {2020},
      note         = {ISSN 2632-8682 not unique: **2 hits**.},
      abstract     = {The rapid growth of COVID-19 cases is causing an increasing
                      death toll and also paralyzing the world economy. De novo
                      drug discovery takes years to move from idea and/or
                      pre-clinic to market, and it is not a short-term solution
                      for the current SARS-CoV-2 pandemic. Drug repurposing is
                      perhaps the only short-term solution, while vaccination is a
                      middle-term solution. Here, we describe the discovery path
                      of the HCV NS3-4A protease inhibitors boceprevir and
                      telaprevir as SARS-CoV-2 main protease (3CLpro) inhibitors.
                      Based on our hypothesis that α-ketoamide drugs can
                      covalently bind to the active site cysteine of the
                      SARS-CoV-2 3CLpro, we performed docking studies, enzyme
                      inhibition and co-crystal structure analyses and finally
                      established that boceprevir, but not telaprevir, inhibits
                      replication of SARS-CoV-2 and mouse hepatitis virus (MHV),
                      another coronavirus, in cell culture. Based on our studies,
                      the HCV drug boceprevir deserves further attention as a
                      repurposed drug for COVID-19 and potentially other
                      coronaviral infections as well.},
      cin          = {DOOR ; HAS-User},
      ddc          = {540},
      cid          = {I:(DE-H253)HAS-User-20120731},
      pnm          = {6G3 - PETRA III (DESY) (POF4-6G3)},
      pid          = {G:(DE-HGF)POF4-6G3},
      experiment   = {EXP:(DE-H253)P-P11-20150101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34041486},
      pmc          = {pmc:PMC8130630},
      UT           = {WOS:000635760100004},
      doi          = {10.1039/D0MD00367K},
      url          = {https://bib-pubdb1.desy.de/record/576716},
}